Conclusion Using screening criteria of serum globulins 445 g/L, one in 20 discretionary laboratory requests resulted in a clinically relevant finding. These results suggest such requesting is worthwhile and should aid future debate on the appropriateness of this practice.
Background Discretionary laboratory requesting of serum protein electrophoresis (SPE) is widespread throughout the UK despite limited evidence to support clinical usefulness. We aimed to examine the clinical usefulness of discretionary SPE requesting on serum samples with globulins 445 g/L by documenting the number of discretionary tests performed and the number of paraproteins identified in an audit period, by determining if such findings led to further investigation/specialty referral, and by identifying the final diagnosis and subsequent management of these patients.
Methods A retrospective one-year audit from July 2002 to June 2003 was carried out using information from biochemistry databases and review of medical records.
Results
Of 1332 discretionary SPEs performed in one year, 72 paraproteins were identified (5.4%). Further clinical information could be obtained in 66 cases. Appropriate follow-up occurred in 84% of cases. The most common diagnosis was monoclonal gammopathy of undetermined significance (56%). Eighteen percent of patients with an identified paraprotein were diagnosed with B-cell malignancies that warranted treatment. A further 6% progressed to requiring treatment during follow-up.
Introduction
Patients suspected of having myeloma or a related Bcell disorder often have serum protein electrophoresis (SPE) requested as a screening test to identify the presence of a paraprotein. In addition, many standard liver function test pro¢les provided by hospital biochemistry departments include total protein and globulin concentrations that, if elevated, raise the suspicion of an underlying paraprotein. A recent questionnaire circulated through the Association for Clinical Biochemistry (ACB) audit committee found that many biochemistry laboratories throughout the UK are performing discretionary requesting of SPE at laboratory level on samples with elevated total protein or globulins. 1 However, the audit also highlighted a number of problems, including the lack of information on follow-up of such results and of their clinical relevance. In an attempt to answer these issues, we aimed to determine the number of discretionary requests performed each year within our Trust and to examine the clinical diagnoses and management of patients that resulted from discretionary requesting.
Methods
The biochemistry department of National Health Service (NHS) Ayrshire and Arran provides service for a population of 367,000. Patient's samples with globulins greater than 45 g/L are considered for discretionary laboratory SPE by biochemistry sta¡ quali¢ed to MRCPath level. Negative modi¢ers include patients with a previous SPE result, those known to, or under the care of haematologists, or those with clinical details that suggest current infection, liver disease or chronic in£ammation. There is no exclusion on the basis of age. A one-year retrospective review of results between July 2002 and June 2003 was executed. Computer records were searched for the number of samples with globulins 445 g/L during this period, for the number of SPE requests added at laboratory level and for the number of paraproteins identi¢ed through discretionary requesting. Medical records for the patients identi¢ed were then reviewed for further clinical information.
Results
During the study period, the biochemistry laboratory received 8339 samples with globulins 445 g/L. Of these, 1332 (16%) had discretionary SPE added. Paraproteins were identi¢ed in 72 patients' samples. Thus, approximately one in 20 discretionary requests provided ¢ndings of clinical interest. Additional clinical information was available from case records for 66 of these patients. Six case records were lost or destroyed.
Of the 66 patients whose case records were available, 42 underwent further investigation. Twenty-four patients received no further investigation. However, of these, 12 died shortly after the blood samples had been taken (three ischaemic heart disease, four solid tumours, ¢ve infection) and three had dementia. In the other nine cases, follow-up was deemed unsatisfactory. Of the 42 patients who received follow-up, 38 were referred to the haematology department for a clinical opinion. Four patients received ongoing follow-up by the general physicians. Of the 38 patients discussed with haematology,34 proceeded to investigations, including bone marrow examination and skeletal survey. Two patients were referred back for general practitioner (GP) follow-up, two had dementia and it was felt clinically inappropriate to proceed with additional tests. Patient characteristics, paraprotein concentrations and diagnoses are shown in Table 1 . The reasons for blood sampling at the time of discretionary requesting of electrophoresis in the patients found to have myeloma are listed in Table 2 . All patients diagnosed with myeloma or Waldenstrom's macroglobulinaemia received treatment. 
Discussion
Discretionary requesting of SPE clearly increases the workload of the biochemistry and haematology departments. For it to be e¡ective, clinicians must be aware of the ¢ndings. We found that, where clinically appropriate, follow-up occurred in 84% of cases. This is an improvement on the ¢ndings of a previous study which found follow-up of 55% of patients with newly diagnosed paraproteins unsatisfactory and may re£ect an attempt to add guidance comments to the results prior to them being sent out. 2 Approximately one in 20 of the discretionary requests resulted in information of clinical interest. Of the 72 patients identi¢ed with paraproteins, 12 were diagnosed with a B-cell malignancy requiring treatment, and a further four progressed to requiring treatment during follow-up. Although it is impossible to know how quickly the patients may have been diagnosed had it not been for discretionary requesting, many of the reasons for blood sampling were not related to a suspicion of underlying B-cell malignancy and no patient had signi¢cant secondary organ damage at the time of diagnosis. In two cases, unnecessary investigations were avoided by the SPE results --a temporal artery biopsy and an endoscopy. However, while prompt diagnosis of myeloma and non-Hodgkin's lymphoma can help reduce the morbidity associated with these diseases, our study showed that the majority of patients identi¢ed with a new paraprotein were diagnosed with monoclonal gammopathy of undetermined signi¢cance (MGUS). No treatment is indicated for patients with MGUS and although such patients have an increased risk of progressing to myeloma or other B-cell malignancy, it is not clear that the recommended monitoring of such patients alters clinical outcome. 3, 4 There remains a scarcity of data regarding the clinical usefulness of discretionary requesting of SPE. Few sites have so far audited their work and comparison is di⁄cult due to widely varying laboratory triggers and modi¢ers in use. Beetham et al. 2 reviewed the use of globulins 438 g/L with certain negative modi¢ers and identi¢ed 49 new paraproteins from 620 extra electrophoretic tests in one year (8%). Six patients were subsequently diagnosed with B-cell malignancies requiring treatment (12%). Other laboratories have assessed the use of total proteins 480 g/L or globulins ranging 440--45 g/L. 5, 6 The criteria chosen by NHS Ayrshire and Arran of globulins 445 g/L meant the number needed to test for a clinically relevant result was 20.
Ethical concern remains over initiating a test not requested by a physician or discussed with a patient. In 2005, the Royal College of Pathologists published guidance on analysis of clinical samples following an initial consultation. 7 Patient consent is likely to involve a request to investigate what is wrong rather than to perform a speci¢c set of analyses and therefore allows for additional tests to be added so long as they are likely to relate to the overall nature of the problem. B-cell malignancies may make patients non-speci¢cally unwell and where an initial result suggests the presence of a paraprotein, we feel proceeding to SPE is warranted. The ¢nding of a paraprotein must be explained to the patient and consent should then be sought for further investigation or specialty referral. Such discretionary requesting may help to solve the clinical problem quicker, potentially reducing patient exposure to unnecessary tests. Ethical concerns speci¢c to discretionary requesting of SPE have recently also been discussed by Beetham et al. 1 Debate will continue about the usefulness of discretionary requesting of SPE. Although hard evidence is lacking, it is our view that early diagnosis of B-cell malignancies may reduce associated morbidity and improve a patient's tolerance of systemic chemotherapy. We suggest such discretionary requesting is worthwhile. It is our hope that this study provides important clinical information to aid future national decisions on whether to continue this practice.
